Detalhe da pesquisa
1.
Sociodemographic characteristics and their association with survival in women with cervical cancer.
BMC Cancer
; 24(1): 161, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38302893
2.
STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER.
Rev Invest Clin
; 72(4): 213-218, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33064702
3.
Standard Treatment with Bevacizumab as Targeted Therapy in Cervical Cancer.
Rev Invest Clin
; 73(3)2020 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32488224
4.
IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER.
Rev Invest Clin
; 72(4): 231-238, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33064705
5.
Cervical cancer prevention program in Mexico disrupted due to COVID-19 pandemic: Challenges and opportunities.
Front Oncol
; 13: 1008560, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36969022
6.
The health system and access to treatment in patients with cervical cancer in Mexico.
Front Oncol
; 12: 1028291, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36530977
7.
Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities.
Cancer Res Treat
; 54(2): 554-562, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34384015
8.
ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer.
Hum Vaccin Immunother
; 17(8): 2617-2625, 2021 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33793380
9.
Standard treatment with bevacizumab as targeted therapy in cervical cancer
Rev. invest. clín
; 72(4): 213-218, Jul.-Aug. 2020.
Artigo
em Inglês
| LILACS | ID: biblio-1251858
10.
Immunotherapy treatment against cervical cancer
Rev. invest. clín
; 72(4): 231-238, Jul.-Aug. 2020.
Artigo
em Inglês
| LILACS | ID: biblio-1251860